Literature DB >> 17533124

In vitro cytotoxicity study on platinum (II) complexes with epoxysuccinates as leaving groups.

Xia Liu1, Hong Shen, Haibin Zhu, Kai Cui, Shaohua Gou.   

Abstract

A series of novel cisplatin-type platinum complexes were designed, characteristic of epoxysuccinates as leaving groups. The pertinent compounds were prepared and characterized by IR, (1)H NMR, and ESI-MS spectra with elementary analyses. The in vitro cytotoxic activities of compounds toward SPC-A1 human lung adenocarcinoma cell line and BGC823 human stomach adenocarcinoma cell line were determined. Biological tests have confirmed that complexes containing 4R,5R-DMID [abbreviation of (4R,5R)-4,5-bis (aminomethyl)-2-isopropyl-1,3-dioxolane] as carrier ligands have greater cytotoxicity toward tumor cells than the corresponding compounds with other carrier ligands. Most platinum complexes with trans-epoxysuccinates usually have higher cytotoxicity than those with cis-epoxysuccinates. Complex 4a shows the most effective among those tested platinum complexes in both cell lines, and its cytotoxicity approached that of cisplatin.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17533124     DOI: 10.1016/j.bmcl.2007.05.014

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  3 in total

1.  Synthesis and Cytotoxic Evaluation of Steroidal Copper (Cu (II)) Complexes.

Authors:  Yanmin Huang; Erbin Kong; Junyan Zhan; Shuang Chen; Chunfang Gan; Zhiping Liu; Liping Pang; Jianguo Cui
Journal:  Bioinorg Chem Appl       Date:  2017-10-18       Impact factor: 7.778

2.  Oxidative DNA double strand breaks and autophagy in the antitumor effect of sterically hindered platinum(II) complexes in NSCLCs.

Authors:  Feihong Chen; Xinyi Wang; Xiufeng Jin; Jian Zhao; Shaohua Gou
Journal:  Oncotarget       Date:  2017-05-09

3.  Diplatin, a Novel and Low-Toxicity Anti-Lung Cancer Platinum Complex, Activation of Cell Death in Tumors via a ROS/JNK/p53-Dependent Pathway, and a Low Rate of Acquired Treatment Resistance.

Authors:  Xixi Lin; Yongliang Jia; Xinwei Dong; Jian Shen; Yachao Jin; Yanyou Li; Fang Wang; Eitan Anenberg; Jiancang Zhou; Jianping Zhu; Xiaoping Chen; Qiangmin Xie; Yicheng Xie
Journal:  Front Pharmacol       Date:  2019-09-11       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.